Details of the Drug Combinations

General Information of This Drug (ID: DM1B3UM)

Drug Name

GDC-0152 DM1B3UM

Synonyms

GDC 0152; GDC0152

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
GDC-0152 + Idarubicin	DCNN6AD	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]
------------------------------------------------------------------------------------

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
GDC-0152 + Caffeine	DCJN7YB	Caffeine	Amyotrophic Lateral Sclerosis	[4]
GDC-0152 + Rabeprazole	DC9QRYC	Rabeprazole	Amyotrophic Lateral Sclerosis	[4]
------------------------------------------------------------------------------------

References

1	Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13.
2	Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
3	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4	ClinicalTrials.gov (NCT02655614) A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis